David M Warburton. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » AnimalsDopamine/metabolismHallucinogens/adverse effectsHumansN-Methyl-3,4-methylenedioxyamphetamine/adverse effectsNeurotoxicity Syndromes/etiologyNeurotoxicity Syndromes/metabolismPrimates
Substances: See more » HallucinogensN-Methyl-3,4-methylenedioxyamphetamineDopamine
Year: 2003 PMID: 14634718 DOI: 10.1007/s00213-003-1678-5
Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN: 0033-3158 Impact factor: 4.530